http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102755319-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae0adfeb8930dcef5c2ca2469e3e5879 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
| filingDate | 2011-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ddb31e36d64710098cf70cb88a65c68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5602fc5768e8d06eb045e77728dcd72a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44d9b78ff45e5591cfc6430a1521c312 |
| publicationDate | 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102755319-B |
| titleOfInvention | Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof |
| abstract | The invention belongs to the field of medicines, and discloses a pharmaceutical composition used for treating cardiovascular and cerebrovascular diseases. According to the pharmaceutical composition provided by the invention, prasugrel or a pharmaceutically acceptable salt thereof, and carvedilol or a pharmaceutically acceptable salt thereof are adopted as pharmaceutically active ingredients. Carvedilol or the pharmaceutically acceptable salt thereof is calculated according to carvedilol, and prasugrel or the pharmaceutically acceptable salt thereof is calculated according to prasugrel. In the pharmaceutical composition, the weight ratio of carvedilol to prasugrel is 1:0.01-100, and preferably 1:0.2-20. When the pharmaceutical composition is applied in treating cardiovascular and cerebrovascular diseases, the effect is comprehensive, the toxic and side effects are low, and patient compliance can be improved. Therefore, the pharmaceutical composition has good medical application prospect. |
| priorityDate | 2011-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.